SAB4200006

Anti-TDP-43 (N-terminal region) antibody produced in rabbit

~1.0 mg/mL, affinity isolated antibody, buffered aqueous solution

• Synonyme(s) : Anti-ALS10, Anti-TARDBP, Anti-TARDP43, Anti-Tar DNA binding protein 43
• Code UNSPSC : 12352203
• Nomenclature NACRES : NA.41

Propriétés

• Source biologique: rabbit
• Conjugué: unconjugated
• Forme d'anticorps: affinity isolated antibody
• Type de produit anticorps: primary antibodies
• Clone: polyclonal
• Forme: buffered aqueous solution
• Poids mol.: antigen ~43 kDa
• Espèces réactives: mouse, human
• Concentration: ~1.0 mg/mL
• Technique(s): immunohistochemistry: 5-10 μg/mL using human or mouse kidney; indirect immunofluorescence: 5-10 μg/mL using HepG2 cells; western blot: 1.5-3.0 μg/mL using HepG2 cell lysates
• Numéro d'accès UniProt: Q13148
• Conditions d'expédition: dry ice
• Température de stockage: −20°C
• Modification post-traductionnelle de la cible: unmodified
• Informations sur le gène: human ... TARDBP(23435) ; mouse ... Tardbp(230908)

Description

Description générale

TDP-43 (TAR DNA binding protein, TARDP) belongs to the family of heterogeneous nuclear ribonucleoproteins (hnRNPs) that bind single stranded RNA. TDP-43 is predominantly localized to the nucleus.

Application

Anti-TDP-43 (N-terminal region) antibody produced in rabbit has been used in:

• immunoblotting
• immunofluorescence
• immunohistochemistry
• immunuprecipitation

Actions biochimiques/physiologiques

TDP-43 is also involved in mediating the transcription regulation of human immune deficiency virus (HIV). TDP-43 has been identified as the major ubiquinated component of cytoplasmic inclusions in frontotemporal lobe degeneration subtype FTLD-U and amyotrophic lateral sclerosis (ALS). Pathological TDP-43 forms abnormal inclusions in neuronal perikarya and neurites, indicating that redistribution of TDP-43 to the cytoplasm is a pathogenic mechanism. Several pathogenic TDP43 mutations have been identified in familial ALS, causing aberrant cleavage of TDP-43 to C-terminal fragments, and predisposing nuclear TDP-43 to redistribute to the cytoplasm and form pathological aggregates. Abnormal phosphorylation of TDP-43 at Ser409/410 has also been observed in frontotemporal lobar degeneration and amyotrophic lateral sclerosis (FTLD-U and ALS) suggesting a toxic gain of function leading to apoptosis.

Forme physique

Solution in 0.01 M phos­phate buffered saline, pH 7.4, containing 15 mM sodium azide.

Clause de non-responsabilité

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Informations sur la sécurité

• Code de la classe de stockage: 10 - Combustible liquids
• Point d'éclair (°F): Not applicable
• Point d'éclair (°C): Not applicable